NasdaqGS:ALECBiotechs
Alector (ALEC) Is Down 54.3% After Latozinemab Phase 3 Failure and Major Restructuring – Has The Bull Case Changed?
Earlier this week, Alector and its partner GSK announced that latozinemab failed to meet safety and efficacy criteria in a Phase 3 clinical trial for frontotemporal dementia due to GRN gene mutations, leading to the discontinuation of related studies and a workforce reduction of approximately 49%.
This setback not only impacts Alector's core pipeline but also coincides with the resignation of its President and Head of R&D, highlighting significant changes in the company's direction.
We'll...